RxDoctor Payments Data

Marwa Adi, MD

Ophthalmology · Chevy Chase, MDNPI 1104820190

Payments from drug & device makers

$2,338in general payments, 2019–2025

Across 38 payments — averaging $61.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rxsight Inc$433
  • Alcon$415
  • Bausch & Lomb Americas Inc.$213
  • AbbVie$209
  • Biotissue Holdings Inc.$163
  • Johnson & Johnson Surgical Vision, Inc.$134
  • plus $771 from 11 others

What the payments were for

  • Travel & lodging$121%
  • Food & beverage$2,30699%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,338 in reported general payments places this provider in the 60th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$490,802
Medicare patients
680
Services billed
2,556

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine46$54,807
Bromfenac Sodium179$17,497
Prednisolone Acetate393$16,788
LumiganBimatoprost11$6,565
Cyclosporine14$5,896
Loteprednol Etabonate34$4,228
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol23$4,030
Difluprednate23$2,455
ValacyclovirValacyclovir Hcl21$2,239
Ketorolac Tromethamine89$1,720
MoxifloxacinMoxifloxacin Hcl42$1,008
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat30$411
Cyclopentolate Hcl42$368
Timolol Maleate45$339
Latanoprost24$330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$209$61,37257 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$125$4,22834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Chevy Chase

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →